“ Our direction is consistent and disciplined: deliver on the AI agenda, reinforce prevention-focused infrastructure and scale our capabilities internationally through structured partnerships. ”
Featured Content
Healthcare is finally moving from a reactive “machine” to a proactive shield. In the latest issue of ISPOR’s Value & Outcomes Spotlight, Editor-in-Chief Zeba M. Khan, PhD, examines how Real-World Evidence is providing the definitive proof that prevention is now an economic and medical necessity. For decades, the guiding principle of public health has…
France’s healthcare and life sciences sector enters 2026 with cautious momentum. With the annual budget finally making its way through the French parliament, stakeholders can look forward to the year ahead in Europe’s second-largest market with increased certainty. And, as this exclusive new report shows, there is plenty to be optimistic about. Healthcare & Life…
Lyon – recently announced as the host of BIO-Europe Spring 2027 – has long played a vital role in global health and, in 2026, it stands as one of Europe’s most investable life sciences hubs. While less well-known internationally than Basel, Barcelona, London, or Paris, Lyon stands out from the pack through its tightly knit…
In Conversation
Kim Moran – SVP & Head of US Rare Disease, UCB
“ In many ways, our move into rare disease is a natural extension of our deep expertise in neurological science ”
Neil Archer – EVP International, Madrigal
“ We achieved what 24 companies before us could not – the first approved treatment for MASH. ”
Kenichi Nakamura – Director, Department of International Clinical Development, National Cancer Center Hospital, Japan
“ Our priority is to strengthen Asia’s role in both the development and the delivery of innovative therapies ”
Marco Billi – International CEO, Eurofarma
“ Latin America has always been a challenging region, marked by regulatory fragmentation, currency volatility, and frequent policy shifts. ”
Sabrina Chan – Senior Executive, HKAPI
“ Hong Kong's Centre for Medical Products Regulation is planned to conduct its first primary review within this year. This represents rapid movement from concept to implementation ”
Inside Ipsen's Home Market Strategy
“ It is both energising and meaningful to serve Ipsen's home market ”
Chen-Yu Cheng – Founder & Chairman, Formosa Group
“ To be successful, you cannot just "do the right thing" – you must be bold enough to take calculated risks ”
Rania Alshami – Chief Business and Strategy Officer, PDC-CRO
“ The burden of rare disease in the region is substantial. We are speaking about a rare patient population of approximately 25 million, comparable to the US and Europe, with a high incidence of metabolic, haematological, and neurological diseases ”
